| CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells R Jitschin, D Saul, M Braun, S Tohumeken, S Völkl, R Kischel, ... Journal for immunotherapy of cancer 6, 1-6, 2018 | 74 | 2018 |
| Virus-like nanostructures for tuning immune response R Mammadov, G Cinar, N Gunduz, M Goktas, H Kayhan, S Tohumeken, ... Scientific reports 5 (1), 16728, 2015 | 47 | 2015 |
| Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2/Akt/mTOR signaling S Tohumeken, R Baur, M Böttcher, A Stoll, R Loschinski, K Panagiotidis, ... Cancer Research 80 (17), 3663-3676, 2020 | 36 | 2020 |
| Diabetic wound regeneration using heparin-mimetic peptide amphiphile gel in db/db mice B Senturk, BM Demircan, AD Ozkan, S Tohumeken, T Delibasi, MO Guler, ... Biomaterials science 5 (7), 1293-1303, 2017 | 28 | 2017 |
| Biotin Functionalized Self‐Assembled Peptide Nanofiber as an Adjuvant for Immunomodulatory Response MB Demircan, S Tohumeken, N Gunduz, MA Khalily, T Tekinay, MO Guler, ... Biotechnology Journal 15 (12), 2000100, 2020 | 17 | 2020 |
| A modular antigen presenting peptide/oligonucleotide nanostructure platform for inducing potent immune response S Tohumeken, N Gunduz, MB Demircan, G Gunay, AE Topal, MA Khalily, ... Advanced Biosystems 1 (5), 1700015, 2017 | 6 | 2017 |
| Virus-like nanostructures for tuning immune response Sci R Mammadov, G Cinar, N Gunduz, M Goktas, H Kayhan, S Tohumeken, ... Rep 5, 16728, 2015 | 6 | 2015 |
| Inhibition of neutral sphingomyelinase 2 impairs HIV-1 envelope formation and substantially delays or eliminates viral rebound SW Yoo, AA Waheed, P Deme, S Tohumeken, R Rais, MD Smith, ... Proceedings of the National Academy of Sciences 120 (28), e2219543120, 2023 | 2 | 2023 |
| CD33/CD3-bispecific T-cell engaging (BiTE®) antibody constructs efficiently target monocytic CD14+ hla-DRlow IDO+ aml-MDSCs D Mougiakakos, D Saul, M Braun, S Tohumeken, R Kischel, L Michael, ... Blood 130, 1363, 2017 | 2 | 2017 |
| The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment EL Hardaker, E Sanseviero, A Karmokar, D Taylor, M Milo, C Michaloglou, ... Nature Communications 15 (1), 1700, 2024 | 1 | 2024 |
| Neuronal deletion of nSMase2 reduces the production of Aβ and directly protects neurons S Tohumeken, P Deme, SW Yoo, S Gupta, R Rais, BS Slusher, ... Neurobiology of Disease 177, 105987, 2023 | 1 | 2023 |
| 957 The ATR-inhibitor ceralasertib modulates the tumor microenvironment and improves the effect of anti-PDL1 by activating type I IFN pathway E Sanseviero, D Taylor, S Tohumeken, M Mai, A Mostafa, M Milo, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Characterization and Targeting of Myeloid-Derived Suppressor Cells in Acute Myeloid Leukemia S Tohumeken Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2020 | | 2020 |
| AML-derived exosomes promote induction of myeloid-derived suppressor cells in an mTOR-signaling-dependent fashion R Jitschin, S Tohumeken, D Saul, H Bruns, M Braun, A Mackensen, ... ONCOLOGY RESEARCH AND TREATMENT 42, 87-87, 2019 | | 2019 |
| Biotinylated Peptide Nanofibers for Modulating the Immune Response Ş Tohumeken PQDT-Global, 2016 | | 2016 |
